title: Improvement of peripheral nervous system manifestations of B-cell non-Hodgkin's lymphoma after rituximab therapy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Briani
authors.forename: Renato
authors.initials: R
authors.lastname: Zambello
authors.forename: Tiziana
authors.initials: T
authors.lastname: Cavallaro
authors.forename: Sergio
authors.initials: S
authors.lastname: Ferrari
authors.forename: Marta
authors.initials: M
authors.lastname: Lucchetta
authors.forename: Sabine
authors.initials: S
authors.lastname: Pollanz
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Grisold
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003711:Demyelinating Diseases / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D000069283:Rituximab; D013497:Sural Nerve / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab